This is the first round of data generated from Gilead's PURPOSE program, a collection of five“With zero infections and 100% efficacy, twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent
ter protection against HIV infection than two other daily pills widely used in high-income countries.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: NBCNewYork - 🏆 270. / 63 Read more »